Drug manufacturer Mallinckrodt’s SpecGx generic pharmaceutical subsidiary is providing refunds for 340B overcharges on 22 NDCs for purchases from Q3 2019 through Q2 2020.
This is the third time this month that a drug manufacturer has announced 340B refunds for
…
In a major blow to the 340B provider community, U.S. Rep. David McKinley, the leading voice for the 340B program in the House Republican caucus, was defeated Tuesday in the West Virginia Republican primary. McKinley will remain in office until
…
Letting drug manufacturers put conditions on 340B drug discounts “would be akin to letting the fox guard the henhouse,” the U.S. Justice Department (DOJ) told federal appeals courts in Philadelphia and Washington, D.C., last night in a pair of filings
…
Drug manufacturer Amgen is providing refunds for overcharges during varying periods over three years on some of its top selling drugs including Enbrel ($4.8 billion in U.S. sales in 2020), Neulasta ($2 billion), Kyprolis ($710 million), Aranesp ($629 million), Epogen
…
After a nine-year delay, federal officials in April 2019 did as Congress ordered and began posting 340B ceiling prices on a secure website. For the first time, providers enrolled in the 340B program had a tool to help them make
…
The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each instance of
…
A federal district judge on Tuesday let Arkansas’ state health center association and a critical access hospital in the state have a role in the drug industry’s lawsuit challenging the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.
U.S. Senior
…
California health centers asked a federal district judge in late April to deny the U.S. Centers for Medicare & Medicaid Services (CMS) motion to dismiss the health centers’ claims against CMS arising over the state’s transfer of Medicaid managed care
…
Senate Finance Committee ranking Republican Chuck Grassley (Iowa) yesterday asked the U.S. Health and Human Services Department of Inspector General (OIG) if it plans to punish seven drug companies over their denials of 340B pricing when hospitals, health centers, and
…
A federal appeals court in Philadelphia, as expected, has decided to consider and rule on AstraZeneca’s 340B contract pharmacy lawsuit in tandem with Sanofi and Novo Nordisk’s 340B contract pharmacy cases.
The U.S. Third Circuit Court of Appeals announced the
…*Sign up for news summaries and alerts from 340B Report